GSK's Zofran Could Lead To Abnormal Heart Rhythms: FDA
Use of GlaxoSmithKline PLC's anti-nausea drug Zofran and its generic equivalents may boost the risk of developing abnormal and potentially fatal heart rhythms, the U.S. Food and Drug Administration announced Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article